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We have evaluated the in vitro activities of seven ﬂuoroquinolones against 69 strains of
Brucella melitensis. According to their minimum inhibitory concentration for 90% growth
(MIC90) values, the most active agent was found to be sparﬂoxacin (MIC90 0.12mg/L)
followed by levoﬂoxacin, ciproﬂoxacin, oﬂoxacin (MIC90 0.50mg/L) and grepaﬂoxacin
(MIC90 1mg/L), gemiﬂoxacin (MIC90 2mg/L) and gatiﬂoxacin (MIC90 4mg/L).
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Brucellosis is a frequently encountered zoonosis in
various regions of the world, including the Med-
iterranean basin. It is one of the major health
problems in rural Turkey. The pathogen is able
to survive andmultiply within the phagocytic cells
of the host. Intracellular killing is inhibited by
mechanisms that are still only partially under-
stood. The most effective treatment is the combi-
nation of doxycycline with either streptomycin or
rifampin. However, relatively frequent side-effects
may restrict the use of these combinations [1]. In
addition, long-term usage of oral doxycycline in
combination with parenteral administration of
streptomycin usually leads to poor patient com-
pliance. An ideal regimen should provide high
penetration rates into macrophages plus greater
stability and activity inside the acidic environment
of phagolysosomes. Fluoroquinolones have been
shown to have good intracellular penetration and
in vitro activity against Brucella spp. However,
their reduced activity in acidic pH could pose a
problem.
The current study evaluates the in vitro
activities of gatiﬂoxacin (Gru¨nenthal, Aachen,
Germany), gemiﬂoxacin (Smithkline Beecham,
Brentford, UK), grepaﬂoxacin (GlaxoWellcome,
Stevenage, UK), levoﬂoxacin (Hoechst Marion
Roussel, Istanbul, Turkey), sparﬂoxacin (Rhone-
Poulenc Rorer, Istanbul, Turkey), ciproﬂoxacin
(Bayer, Wuppertal-Elberfeld, Germany), and
oﬂoxacin (Hoechst Marion Roussel) against 69
Brucella melitensis isolates that were collected
between 1991 and 1999 from blood and bone-
marrow cultures of adult patients with acute bru-
cellosis at Hacettepe University Hospital, Ankara,
Turkey. Only one isolate per patient was included.
The organisms were identiﬁed to species level by
conventional methods and on the basis of not
requiring CO2 and not producing H2S [2].They
were stored at 70 8C and subcultured twice
before susceptibility testing and a Class II biolo-
gical safety cabinet was used. Minimum inhibitory
concentrations (MICs) were determined by the
agar dilution technique with Mueller–Hinton agar
(Merck,Darmstodt,Germany), supplementedwith
1% hemoglobin and 1% PoliviteX (bioMerie´ux,
Lyon, France), using an inoculum of 104 colony-
forming units (CFU) per spot. The inoculations
were made by a multipoint inoculator (Denley,
Nivelles, Belgium) and the MIC values were
deﬁned as the lowest concentration of the antibiotic
that completely inhibited growth.
The MIC50 and MIC90 values of antibiotics for
these isolates are shown in Table 1. According to
their MIC90 values, the most active quinolone was
sparﬂoxacin, followed by levoﬂoxacin, ciproﬂox-
acin, oﬂoxacin, grepaﬂoxacin, gemiﬂoxacin and
gatiﬂoxacin. Sparﬂoxacin’s activity was four-fold
to 32-fold greater than the other ﬂuoroquinolones
tested.
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A limited number of studies have examined
the activity of new ﬂuoroquinolones against
Brucella isolates. Qadri et al. [3] reported that
the MIC90 of lomeﬂoxacin (0.5mg/L) was similar
to those of ciproﬂoxacin, tetracycline and genta-
micin. Garcia-Rodriguez et al. [4] found clinaﬂox-
acin to be the most active compound (MIC90
0.06mg/L) when compared to four other experi-
mental quinolones and ciproﬂoxacin. Trujillano-
Martin et al. [5] tested the in vitro activities of
sitaﬂoxacin, ciproﬂoxacin, oﬂoxacin, levoﬂoxacin,
trovaﬂoxacin, moxiﬂoxacin, grepaﬂoxacin and
gatiﬂoxacin against 160 B. melitensis strains. They
found sitaﬂoxacin to be the most active, with an
MIC90 value of 0.12mg/L. Similar to our results,
the MIC90 values of the other tested ﬂuoroquino-
lones were as follows: levoﬂoxacin (0.5mg/L),
ciproﬂoxacin, trovaﬂoxacin and moxiﬂoxacin
(1mg/L); oﬂoxacin, grepaﬂoxacin and gatiﬂoxacin
(2mg/L).
Although the emergence of resistance to anti-
bacterial agents is not a known factor relating to
relapses of brucellosis, it has been shown that
factors such as pH, inoculum size and medium
have signiﬁcant effects on susceptibility results
[6–8]. The activities of study drugs at pH5.0 were
not tested in the present work. However, we have
previously shown that both ciproﬂoxacin and
oﬂoxacin were less active at pH5.0 against B.
melitensis [6]. Fluoroquinolone monotherapy was
found to be disappointing for the treatment of
brucellosis in clinical trials [9,10]. This may well
be correlated with their reduced activity at acidic
pH in phagolysosomes.
In a previous trial, we reported that oﬂoxacin in
combination with rifampin was as effective as
doxycycline plus rifampin in the treatment of
brucellosis, despite the fact later shown that less
synergy existed between rifampin and oﬂoxacin
than rifampin and doxycycline at either pH7.0 or
pH5.0 [1,6]. The discrepancy between in vitro and
in vivo results could be explained by the fact that
quinolones and rifampin may produce antibacter-
ial activity at different sites in vivo (i.e. rifampin is
most active in phagolysosomeswith acidic pH and
quinolones are highly active in the serum where
pH is >7.0), hence eluding the in vitro antagonism
[6].
This study provides further support for our
belief that the activities of new quinolones against
B. melitensis are similar to those of older quino-
lones. Based on these results and those of other
trials it seems that the newer quinolones, either
alone or in combination with rifampin, should
not replace the established regimens for the
treatment of brucellosis. However, such com-
binations may provide an alternative, especially
in cases of intolerance to either doxycycline or
streptomycin.
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